GAITHERSBURG, Md., Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023. Details of the event and replay are as follows:
Conference call details: |
|
Date: | November 9, 2023 |
Time: | 8:30 a.m. U.S. EST |
Dial-in number: | (877) 550-1858 (Domestic) or (848) 488-9160 (International) |
Passcode: | 1754341 |
Webcast: | ir.novavax.com/events |
- Participants will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details: |
|
Date: | Available starting at 11:30 a.m. EST, November 9, 2023, until
11:59 p.m. U.S. EST, November 16, 2023 |
Dial-in number: | (800) 645-7964 (Domestic) or (757) 849-6722 (International) |
Passcode: | 5567# |
Webcast: | ir.novavax.com/events, until February 7, 2024 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2023-financial-results-and-operational-highlights-on-november-9-2023-301974716.html
SOURCE NOVAVAX, INC